{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:25:49Z","timestamp":1783938349527,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["Y20240066"],"award-info":[{"award-number":["Y20240066"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116351","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T23:40:41Z","timestamp":1771198841000},"page":"116351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3"],"prefix":"10.1016","volume":"174","author":[{"given":"Tianyang","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2026.116351_bb0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"issue":"716","key":"10.1016\/j.intimp.2026.116351_bb0010","doi-asserted-by":"crossref","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.116351_bb0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2026.116351_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.intimp.2026.116351_bb0025","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated Steatotic liver disease (MASLD)","volume":"16","author":"Benede-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.intimp.2026.116351_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/biom14040476","article-title":"Innate immunity and MASLD","volume":"14","author":"Meyer","year":"2024","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.intimp.2026.116351_bb0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116351_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the inflammasome in liver disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116351_bb0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116351_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116351_bb0055","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116351_bb0060","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2026.116351_bb0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3350\/cmh.2024.0268","article-title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD","volume":"30","author":"Sun","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116351_bb0070","doi-asserted-by":"crossref","first-page":"97002","DOI":"10.1289\/EHP13913","article-title":"Long-term exposure to polystyrene microspheres and high-fat diet-induced obesity in mice: evaluating a role for microbiota dysbiosis","volume":"132","author":"Zhai","year":"2024","journal-title":"Environ. Health Perspect."},{"issue":"6","key":"10.1016\/j.intimp.2026.116351_bb0075","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41401-022-01040-z","article-title":"Tabersonine, a natural NLRP3 inhibitor, suppresses inflammasome activation in macrophages and attenuate NLRP3-driven diseases in mice","volume":"44","author":"Xu","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.intimp.2026.116351_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2022.10.028","article-title":"Hepatocyte-specific mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice","volume":"78","author":"Chen","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116351_bb0085","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116351_bb0090","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116351_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2026.116351_bb0100","doi-asserted-by":"crossref","unstructured":"Q. Lv, Y. Zhang, J. Wang, W. Lin, Y. Xie, H. Yang, X. Yin, Z. Zhu, Y. Cui, Y. Hu, L. Zeng, Y. Zhang, X. Chen, J. Liu, L. Hu, Dehydrocostus lactone effectively alleviates inflammatory diseases by covalently and irreversibly targeting NLRP3, MedComm (2020) 6(9) (2025) e70367.","DOI":"10.1002\/mco2.70367"},{"key":"10.1016\/j.intimp.2026.116351_bb0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"7761","key":"10.1016\/j.intimp.2026.116351_bb0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"issue":"7944","key":"10.1016\/j.intimp.2026.116351_bb0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2026.116351_bb0120","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.apsb.2022.09.014","article-title":"Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2026.116351_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116360","article-title":"Chloranthalactone B covalently binds to the NACHT domain of NLRP3 to attenuate NLRP3-driven inflammation","volume":"226","author":"Tang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116351_bb0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.02.031","article-title":"Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116351_bb0135","article-title":"Secondary Metabolites against Oxidative Stress-Related Human Diseases","volume":"8","author":"Tavares","year":"2019","journal-title":"Antioxidants (Basel)"},{"issue":"30","key":"10.1016\/j.intimp.2026.116351_bb0140","doi-asserted-by":"crossref","first-page":"11680","DOI":"10.1021\/acs.jafc.3c02497","article-title":"Discovery of natural sesquiterpene lactone 1-O-Acetylbritannilactone analogues bearing oxadiazole, triazole, or imidazole scaffolds for the development of new fungicidal candidates","volume":"71","author":"Zhi","year":"2023","journal-title":"J. Agric. Food Chem."},{"issue":"21","key":"10.1016\/j.intimp.2026.116351_bb0145","doi-asserted-by":"crossref","first-page":"18122","DOI":"10.1021\/acsomega.2c01681","article-title":"1-O-Actylbritannilactone ameliorates alcohol-induced hepatotoxicity through regulation of ROS\/Akt\/NF-kappaB-mediated apoptosis and inflammation","volume":"7","author":"Xie","year":"2022","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.intimp.2026.116351_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28114320","article-title":"The effects of 1-O-Acetylbritannilactone isolated from Inula britannica flowers on human neutrophil elastase and inflammation of RAW 264.7 cells and zebrafish larvae","volume":"28","author":"Lee","year":"2023","journal-title":"Molecules"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2026.116351_bb0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.phymed.2008.08.003","article-title":"1,6-O,O-diacetylbritannilactones inhibits IkappaB kinase beta-dependent NF-kappaB activation","volume":"16","author":"Liu","year":"2009","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.intimp.2026.116351_bb0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.gendis.2023.01.009","article-title":"Fantastic voyage: the journey of NLRP3 inflammasome activation","volume":"11","author":"Que","year":"2024","journal-title":"Genes Dis"},{"issue":"13","key":"10.1016\/j.intimp.2026.116351_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116351_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116679","article-title":"NLRP3 inflammasome and its role in autoimmune diseases: a promising therapeutic target","volume":"175","author":"Ren","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2026.116351_bb0175","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2026.116351_bb0180","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem. Soc. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2026.116351_bb0185","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116351_bb0190","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2020.07.016","article-title":"The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation","volume":"32","author":"Hooftman","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.116351_bb0195","article-title":"The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116351_bb0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116351_bb0205","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116351_bb0210","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2020.11.009","article-title":"NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice","volume":"534","author":"Wang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:39:56Z","timestamp":1773286796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"alternative-id":["S1567576926001955"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116351","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116351"}}